NCT02229760终止1 期
Effect of Steady State TPV/r 500 mg/200 mg on Intracellular Concentrations of Zidovudine Triphosphate and Carbovir Triphosphate
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 主要终点
- AUC0-12h (Area under curve) of carbovir-TP
研究概览
简要总结
To determine the effect of steady-state tipranavir 500 mg/ritonavir 200 mg (TPV/r) on intracellular concentrations of zidovudine triphosphate (ZDV-TP) and carbovir triphosphate (CBV-TP) and plasma viral load
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent before study participation
- •Age >18 and <60 years
- •Female patients of child-bearing potential who use a barrier contraceptive method for at least 12 weeks before administration of study medication, during the study and for 28 days after administration of study medication has ended and who have a negative pregnancy test result
- •Ability to swallow capsules without difficulty
- •A Body Mass Index (BMI) between 18 and 29 kg/m2
- •Reasonable probability of completing the study
- •A medical history, physical examination, and electrocardiogram (ECG) before entering the study
- •Agreement to abstain from alcohol from Day -2 to Day 24
- •Agreement to abstain from ingesting grapefruit, grapefruit juice, Seville oranges or orange marmalade from Day -2 to Day 24
- •Negative urine drug screen for drugs of abuse
- •Documented HIV-1 RNA load (by PCR) at screening of <50 copies/mL for at least 3 months and on a stable ZDV or ABC regimen for at least 6 months. Acceptable documentation included laboratory data, letter, or verbal report from another provider noted in the patient's records
- •All HIV-infected patients must be TPV naïve and must not have received a PI based regimen within 6 months of enrollment
排除标准
- •Female patients who had a positive serum pregnancy test during the screening period of Day -14 to Day -7 or who plan to breast-feed at time (Day 0 to 30 after TPV/r administration)
- •Use of any other investigational medicine within 30 days before Day 0
- •Use of any known CYP3A4 altering drug (i.e., phenothiazines, cimetidine, barbiturates, ketoconazole, fluconazole, rifampin, steroids and herbal medications) within 30 days before Day
- •No antibiotics were permitted within 10 days before Day 0
- •Ingestion of grapefruit, grapefruit juice, Seville oranges, or orange marmalade within 2 days of study entry (Day 0)
- •Blood or plasma donations (>100 mL total) for research or altruistic reasons within 30 days before Day 0
- •Seated systolic blood pressure either <100 mm Hg or >150 mm Hg; resting heart rate either <50 beats/minute or >90 beats/minute
- •History of any illness (including malabsorption, irregular food intake, gastrointestinal intolerance, or allergy) that, in the opinion of the investigator, might confound the results of the study or pose additional risks in administering TPV/r
- •Any acute illness within 2 weeks before Day 0
- •Patients who were currently taking any over-the-counter medication within 7 days before Day 0, or who were currently taking any prescription drug that, in the opinion of the investigator (in consultation with the BI medical monitor or pharmacokineticist), would have interfered with either the absorption, distribution, or metabolism of TPV or ritonavir
- •Hypersensitivity to TPV, ritonavir, or sulfonamide containing drugs, or antiretroviral drugs (marketed or experimental use as part of clinical research studies)
- •Sulfonamide allergy, that in the opinion of the investigator, might confound the results of the study or pose additional risks in administering TPV/r
- •Any laboratory value outside the normal reference range that is of clinical relevance at screening, according to the judgment of the investigator (i.e., aspartate aminotransferase and alanine aminotransferase levels 2.5-fold and 2.5-fold higher than the upper normal limit, respectively)
- •Based on the compliance diary, the patient had less than 100% documented compliance for 7-14 days of background Antiretroviral (ARV) (i.e., ZDV and ABC) medications before Day -5 to 0 (visit 2)
- •Use of any protease inhibitors (i.e., fosamprenavir, amprenavir, indinavir, saquinavir, lopinavir, ritonavir, atazanavir, and nelfinavir) within 6 months of enrollment
- •Patients who are co-infected with active Hepatitis B and/or C as determined by hepatitis serology.
- •Use of any anti-platelet medications (e.g. aspirin, dipyridamole, clopidogrel, or any over the counter anti-platelet medicine).
研究组 & 干预措施
TPV/r (Tipranavir co-administered with low dose ritonavir)
Experimental
干预措施: Tipranavir capsules (Drug)
TPV/r (Tipranavir co-administered with low dose ritonavir)
Experimental
干预措施: Ritonavir capsules (Drug)
结局指标
主要结局
AUC0-12h (Area under curve) of carbovir-TP
时间窗: Up to 12 hours after drug administration
AUC0-12h (Area under curve) of intracellular ZDV-TP
时间窗: Up to 12 hours after drug administration
次要结局
- Concentration of Zidovudine (ZDV) in plasma(Up to 14 days after drug administration)
- Concentration of Tipranavir (TPV) in plasma(Up to 14 days after drug administration)
- Percentage of patients with viral load (VL) <50(Up to 14 days after last drug adminnistration)
- Cp12h (Trough plasma concentration)(Up to 14 days after drug administration)
- Number of patients with clinical significant findings in laboratory measurements(Up to 14 days after last drug administration)
- Concentration of Abacavir (ABC) in plasma(Up to 14 days after drug administration)
- Concentration of ritonavir in plasma(Up to 14 days after drug administration)
- AUC0-12h (Area under curve)(Up to 14 days after drug administration)
- Number of patients with adverse events(Up to 14 days after last drug adminnistration)
- Number of patients with clinical significant findings in vital sings(Up to 14 days after last drug administration)
- Cmax (Maximum observed concentration)(Up to 14 days after drug administration)
- Number of patients with clinical significant findings in physical examinations(Up to 14 days after last drug administration)
研究者
相似试验
已完成
1 期
Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy SubjectsHealthyNCT02251795Boehringer Ingelheim52
已完成
1 期
Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy VolunteersHealthyNCT02243553Boehringer Ingelheim34
已完成
1 期
Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male SubjectsHealthyNCT02248883Boehringer Ingelheim81
已完成
1 期
Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male SubjectsHealthyNCT02251158Boehringer Ingelheim30
已完成
1 期
Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy VolunteersHealthyNCT02245269Boehringer Ingelheim23